Dr. Beth Karlan is a leader in the field of research on early detection of ovarian cancer. She has received research grants from the Department of Defense, National Institutes of Health and the American Cancer Institute. Her research interests include the genetic definition and phenotypic determinants of human ovarian carcinomas, molecular biomarker discovery and inherited cancer susceptibility. This year, she is our winner of the Rosalind Franklin Excellence in Ovarian Cancer Research Award due to her commitment to innovative ovarian cancer research.
Related Topics
The Overview: May 2026
When Ovarian Cancer Research Alliance (OCRA) announced the launch of the Community Accelerated Research Exchange on World Ovarian Cancer Day, the response was immediate. More than 280 media mentions. Over 171 million people reached. Television and radio coverage in English and Spanish, in markets from San Francisco to Albany. The excitement is building—and it’s just … Continued
OCRA’s Research Exchange Announcement Reaches Over 171 Million
AI-Powered Platform Launch Sparks Nationwide Conversation The response to OCRA’s launch of the Community Accelerated Research Exchange was immediate and far-reaching. News outlets across the country picked up the story, generating more than 280 media mentions and reaching over 171 million people—a sign of just how much this groundbreaking platform, designed to connect patients, researchers, … Continued
OCRA-Funded ROCCA Platform Launches to Accelerate Rare Ovarian Cancer Research
OCRA is proud to announce the launch of the Rare Ovarian Cancer Collaborative Analytics (ROCCA) Platform, an international federated data network funded by OCRA to connect researchers globally and accelerate breakthroughs in rare ovarian cancer research. A collaborative approach to research for rare ovarian cancer ROCCA is launching with two foundational projects: one in mucinous … Continued
